전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved318 programs
CGTLimited DatastaleVaxcell Bio, Co., Ltd.Phase 1

Autologous Natural Killer Cell Therapy (Autologous Natural Killer Cell Therapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 46Status Recruiting
CGTLimited DatastaleGeneplus-Beijing Co. Ltd.Phase 2

DC-CIK (DC-CIK)

Renal Cell Carcinoma · Renal Neoplasma

#RenalNeoplasma#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 46Status Recruiting
AntibodyLimited DatastaleGruppo Oncologico del Nord-OvestPhase 2

Balstilimab (Balstilimab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#ResectableColorectalCarcinoma+1
Trials 45Status Recruiting
CGTLimited DatastaleAcrotech Biopharma Inc.Phase 1

Belinostat (Belinostat)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · Adult T-cell Leukemia-Lymphoma

#AdultT-cellLeukemia-Lymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 45Status Discontinued
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Neurokinin-1 receptor antagonist (Neurokinin-1 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#antibody-drug-conjugate#Carcinoma+2
Trials 45Status Recruiting
AntibodyLimited DatastaleHuiKai LiPhase 2

Pucotenlimab (Pucotenlimab)

Biliary Tract Cancer (BTC); EGFR-positive Advanced Biliary Tract Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#Antibody#Phase2#monoclonal-antibody#BiliaryTractCancerBTC+2
Trials 42Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCDeruxtecan in Patients With…Phase 2

I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd))

Carcinoma, Non-Small-Cell Lung · Small-Cell Lung Cancer

#Small-CellLungCancer#ADC#Phase2#antibody-drug-conjugate#Carcinoma+4
Trials 41Status Recruiting
CGTLimited DatastaleImmunityBio, Inc.Phase 2

haNK (haNK)

Melanoma · Merkel Cell Carcinoma

#MerkelCellCarcinoma#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 40Status Discontinued
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Preclinical

CAR-GPC3 T Cells (CAR-GPC3 T Cells)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 39Status Active
AntibodyLimited DatastaleGruppo Oncologico del Nord-OvestPhase 2

Botensilimab (Botensilimab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#ResectableColorectalCarcinoma+1
Trials 38Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

Hu5F9-G4 (Magrolimab, Magrolimab (Hu5F9-G4))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#monoclonal-antibody#BladderCancer+2
Trials 35Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 1

CD70 CAR T-cells (CD70 CAR T-cells)

Metastatic Tumor; Renal Cell Carcinoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 31Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, HER2, pyrotinib + pertuzumab/trastuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#SalivaryGlandCarcinoma+2
Trials 30Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

Toripalimab + cetuximab (3cycles, 3cycles (Toripalimab + cetuximab))

Head and Neck Squamous Cell Carcinoma; Neoadjuvant Therapy · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#NeoadjuvantTherapy+1
Trials 29Status Recruiting
AntibodyLimited DatastaleAbbViePhase 3

Budigalimab (Budigalimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 29Status Recruiting
ADCLimited DatastaleLepu Medical Technology (Beijin…Phase 3

Becotatug Vedotin (Becotatug Vedotin)

Nasopharyngeal Cancinoma (NPC) · Adenoid Cystic Carcinoma

#AdenoidCysticCarcinoma#ADC#Phase3#antibody-drug-conjugate#NasopharyngealCancinomaNPC+1
Trials 28Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Drug: Disitamab Vedotin)

Upper Urinary Tract Urothelial Carcinoma · Upper Urinary Tract Urothelial Carcinoma

#UpperUrinaryTractUrothelialCarci#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 26Status Recruiting
ADCStandard DatabasestaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SalivaryGlandCarcinoma+2
Trials 23Status Recruiting
AntibodyLimited DatastaleImmunityBio, Inc.Phase 2

Necitumumab (Necitumumab)

Squamous Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#SquamousCellCarcinoma+1
Trials 23Status Discontinued
AntibodyLimited DatastalePfizerPhase 1

sasanlimab (sasanlimab)

Carcinoma, Pancreatic Ductal; Colorectal Neoplasms · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase1#monoclonal-antibody#Carcinoma+3
Trials 23Status Discontinued

3 / 16 pages

← PreviousNext →